<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2489">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128760</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00244-37</org_study_id>
    <nct_id>NCT05128760</nct_id>
  </id_info>
  <brief_title>Impact of Antiphospholipid Antibodies on Thrombin Generation During Sars-CoV2 Infection (TACIT2 Study)</brief_title>
  <acronym>TACIT2</acronym>
  <official_title>Impact of Antiphospholipid Antibodies on Thrombin Generation During Sars-CoV2 Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Context: Until 70% of thrombotic event are reported during Sars-CoV2 infection.&#xD;
      Antiphospholipid antibodies (aPL) tests are often positive. We aim to determine if aPL&#xD;
      positivity is involved in thrombose of Sars-CoV2 infection investigating the effect of aPL on&#xD;
      thrombin generation (TG) and leucocyte pathway activation (neutrophils extracellular traps&#xD;
      (NETs) and activation of triggering receptor expressed on myeloid cells 1 (TREM-1)).&#xD;
&#xD;
      Method: We will compare plasma from five groups of subjects: patients with antiphospholipid&#xD;
      syndrome (APS) and patients hospitalized for Sars-CoV-2 infection with or without aPL, and as&#xD;
      control, patients with acute venous thromboembolism event and healthy volunteers. For each&#xD;
      subject, we will analyze aPL, activated protein C (APC) resistance measured by TG and&#xD;
      leukocytes markers as circulating neutrophils extracellular traps (NETs) and soluble&#xD;
      triggering receptor expressed on myeloid cells one (sTREM-1). We will control aPL test at&#xD;
      three month and analyze their persistent positivity and association with thrombotic event.&#xD;
&#xD;
      Results: we hypothesize that patients with COVID-19 and aPL will have a similar aPL and level&#xD;
      of APS resistance that patients with APS. Also, we think that circulating NETs and sTREM-1&#xD;
      levels will be more important in patients with COVID-19 with aPL than patients without aPL&#xD;
      and similar in patients with COVID-19 and aPL and patients with APS.&#xD;
&#xD;
      Conclusion: our study will be the first to analyze the potential role of aPL on APC&#xD;
      resistance measured by TG and neutrophil activation in COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of activated protein C resistance and comparison between groups</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>frequency of positivity of each aPL test and comparison between groups</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of leucocytes activation markers and comparison between groups</measure>
    <time_frame>at inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of persistent aPL test positivity and comparison between groups</measure>
    <time_frame>at three month</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">161</enrollment>
  <condition>Antiphospholipid Syndrome</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Patients with COVID-19 and aPL positivity</arm_group_label>
    <description>Patient with COVID-19 and aPL test positivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with COVID-19 without aPL positivity</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>APS patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Disease control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>characterization of aPL</intervention_name>
    <description>characterization of aPL profile, GT profile and leukocytes activations markers (NETs, TREM-1)</description>
    <arm_group_label>APS patients</arm_group_label>
    <arm_group_label>Disease control</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Patients with COVID-19 and aPL positivity</arm_group_label>
    <arm_group_label>Patients with COVID-19 without aPL positivity</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Five groups of subjects will be enrolled in the study :&#xD;
&#xD;
          1. patients hospitalized for à COVID-19 with aPL&#xD;
&#xD;
          2. patients hospitalized for à COVID-19 without aPL&#xD;
&#xD;
          3. patients with APS&#xD;
&#xD;
          4. as control, patients with acute venous thromboembolism disease&#xD;
&#xD;
          5. as control, healthy volunteers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient receiving a comprehensive information about the study, and not opposed to&#xD;
             participate&#xD;
&#xD;
             + one criterion among :&#xD;
&#xD;
          -  patient hospitalized fo a COVID-19&#xD;
&#xD;
          -  Patient with known APS&#xD;
&#xD;
          -  Patients hospitalized for an acute venous thromboembolism event aPL positivity or&#xD;
             COVID-19&#xD;
&#xD;
          -  healthy volunteers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  For all participants : pregnancy, age below 18 years-old, absence of written informed&#xD;
             consent , autoimmune or inflammatory disease except antiphospholipid syndrome&#xD;
&#xD;
          -  For patients with COVID-19: previous aPL positivity (before COVID-19 infection)&#xD;
&#xD;
          -  For patients with APS: previous symptomatic COVID-19 infection&#xD;
&#xD;
          -  For patients control with acute venous thromboembolism event: previous symptomatic&#xD;
             COVID-19 infection, infection or inflammatory disease in flare at the time of&#xD;
             thromboembolism event, known aPL positivity&#xD;
&#xD;
          -  For Healthy volunteers: history of thrombosis (venous, arterial or small vessels),&#xD;
             previous symptomatic COVID-19 infection, infection or inflammatory disease in flare at&#xD;
             the time of inclusion, known aPL positivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis G Wahl, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHRU of Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane Zuily, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU of Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Virginie Dufrost, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU of Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Virginie DUFROST, MD</last_name>
    <phone>+33383157828</phone>
    <email>v.dufrost@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephane Zuily, MD, PhD</last_name>
    <phone>+33383157354</phone>
    <email>s.zuily@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginie Dufrost</name>
      <address>
        <city>Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Virginie Dufrost, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane Zuily, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis G Wahl, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Foret, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP, MacDonald V, Green L, Sivapalaratnam S, Pasi KJ, MacCallum P. Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19. N Engl J Med. 2020 Jul 16;383(3):288-290. doi: 10.1056/NEJMc2013656. Epub 2020 May 5.</citation>
    <PMID>32369280</PMID>
  </reference>
  <reference>
    <citation>Zuily S, de Laat B, Guillemin F, Kelchtermans H, Magy-Bertrand N, Desmurs-Clavel H, Lambert M, Poindron V, de Maistre E, Dufrost V, Risse J, Shums Z, Norman GL, de Groot PG, Lacolley P, Lecompte T, Regnault V, Wahl D. Anti-Domain I β2-Glycoprotein I Antibodies and Activated Protein C Resistance Predict Thrombosis in Antiphospholipid Syndrome: TAC(I)T Study. J Appl Lab Med. 2020 Nov 1;5(6):1242-1252. doi: 10.1093/jalm/jfaa072.</citation>
    <PMID>32572467</PMID>
  </reference>
  <reference>
    <citation>Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, Núñez-Álvarez C, Hernández-Ramírez D, Bockenstedt PL, Liaw PC, Cabral AR, Knight JS. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol. 2015 Nov;67(11):2990-3003. doi: 10.1002/art.39247.</citation>
    <PMID>26097119</PMID>
  </reference>
  <reference>
    <citation>Edel Y, Kliminski V, Pokroy-Shapira E, Oren S, Dortort Lazar A, Pri-Paz Basson Y, Egbaria M, Molad Y. Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome. Arthritis Res Ther. 2019 Jan 7;21(1):10. doi: 10.1186/s13075-018-1779-5.</citation>
    <PMID>30616644</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 18, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Virginie Dufrost</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

